GlassScriptPhysician profile
Marcela Campo
NPI 1831390574
$1,060.81
in general payments reported to CMS, 2019-2025
12 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2022: $229 · 2023: $236 · 2024: $161 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $233.88 | 2022-2025 | Dalvance |
| Shionogi INC | $155.14 | 2022-2023 | Fetroja |
| Merck Sharp & Dohme LLC | $142.94 | 2019-2023 | Dificid, Zerbaxa, Recarbrio |
| Melinta Therapeutics, LLC | $124.72 | 2022 | |
| Boston Scientific Corporation | $121.30 | 2019 | |
| Gilead Sciences, INC. | $113.84 | 2023-2025 | Veklury |
| Viiv Healthcare Company | $42.96 | 2019 | |
| Insmed, INC. | $33.91 | 2025 | Arikayce |
| Cumberland Pharmaceuticals, INC. | $32.52 | 2024-2025 | Vibativ |
| La Jolla Pharmaceutical Company | $25.54 | 2024 | Xacduro |
| Emd Serono, INC. | $20.70 | 2024 | |
| Paratek Pharmaceuticals, INC. | $13.36 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcela Campo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.